Pharma companies must disclose their formulas during the clinical approval process, often many years before taking the product to market.
Pharmaceutical companies are therefore highly dependent on Intellectual Property Rights. And securing one’s IP rights early in the process is often crucial to protect the innovation from competitors in the market.
The European Patent Office’s, shows that pharma is currently the fastest growing area within patent filing. This only highlights the importance of IPR in the industry.
Plougmann Vingtoft’s dedicated experts within pharmaceutical IPR know the importance of protecting and managing the rights to your IP and are always up to date on the latest developments in the field.
“IP is a pharmaceutical or biotech company’s most valuable resource, and its protection is a key factor for successful businesses. For more than three decades now, we have made it our specialty to manage commercially important patents,” says, European patent attorney and partner at Plougmann Vingtoft.
How we can help
Plougmann Vingtoft’s IP attorneys have extensive experience working with the pharmaceutical industry. Further, they have a proven track record of successfully prosecuting and protecting commercially important patents for companies such as Bayer AG and Novozymes.
We provide a vast range of IPR services, including:
- Freedom-to-operate analysis (FTO): Identifying your market position and the existing patent rights
- Patentability assessment
- Drafting and filing of patent applications, incl. casework and IP administration
- Strategic consulting that helps you utilize your IP rights in order to increase your company’s market value
- Consulting in the transition from early-stage development to commercialization
Ourcan assist you in building an IPR strategy that will help you protect your ideas and achieve a competitive edge.
If you are ready for a non-committal introductory meeting about how we can assist you with IPR consulting, feel free to reach out to one of the experts below or by filling out this.